Turkcell Iletisim Hizmetleri A.S. (IST:TCELL)

Checkpoint Therapeutics Income Statement

Financials in millions TRY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	172,067	166,671	154,653	93,487	35,921	29,104
Revenue Growth (YoY)	2.83%	7.77%	65.43%	160.26%	23.42%	15.78%
Cost of Revenue	126,458	125,512	121,987	81,377	25,218	20,334
Gross Profit	45,609	41,159	32,666	12,110	10,703	8,770
Selling, General & Admin	18,948	17,763	13,052	7,085	2,670	2,102
Other Operating Expenses	-11,183	-11,142	-12,999	1,591	484.31	453.48
Operating Expenses	7,765	6,621	53.15	8,676	3,154	2,556
Operating Income	37,844	34,538	32,613	3,434	7,549	6,214
Interest Expense	-26,084	-25,535	-48,809	-5,475	-1,199	-1,001
Interest & Investment Income	6,039	4,506	17,014	6,291	1,470	758.81
Earnings From Equity Investments	-3,949	-3,163	2,202	522.22	90.09	-13.78
Currency Exchange Gain (Loss)	1,925	-	-	-8,016	-5,773	-2,520
Other Non Operating Income (Expenses)	3,024	5,851	5,511	7,078	2,764	1,662
EBT Excluding Unusual Items	18,799	16,197	8,530	3,834	4,901	5,100
Merger & Restructuring Charges	19.93	-	-	-	-5.99	-13.05
Gain (Loss) on Sale of Investments	-771.01	-108.28	-33.43	-35.5	-	-31.54
Gain (Loss) on Sale of Assets	-37.93	-	-	-	-	-
Asset Writedown	-135.62	-135.56	2.06	-391.62	-39.84	-22.65
Legal Settlements	-83.6	-	-	-156.02	-313.59	-406.16
Other Unusual Items	-3.74	-	-	-	-	-
Pretax Income	17,787	15,953	8,499	3,251	4,541	4,627
Income Tax Expense	6,502	4,866	-6,751	-2,785	-490.18	387.19
Earnings From Continuing Operations	11,285	11,087	15,250	6,036	5,031	4,240
Earnings From Discontinued Operations	11,681	12,428	2,844	842.37	-	-
Net Income to Company	22,966	23,515	18,094	6,879	5,031	4,240
Minority Interest in Earnings	1.05	8.56	31.4	1.58	-0.18	-2.53
Net Income	22,967	23,523	18,125	6,880	5,031	4,237
Net Income to Common	22,967	23,523	18,125	6,880	5,031	4,237
Net Income Growth	4.13%	29.78%	163.43%	36.76%	18.74%	30.51%
Shares Outstanding (Basic)	2,183	2,181	2,182	2,183	2,183	2,183
Shares Outstanding (Diluted)	2,183	2,181	2,182	2,183	2,183	2,183
Shares Change (YoY)	0.32%	-0.05%	-0.05%	-	-	-0.04%
EPS (Basic)	10.52	10.79	8.31	3.15	2.30	1.94
EPS (Diluted)	10.52	10.79	8.31	3.15	2.30	1.94
EPS Growth	3.80%	29.85%	163.55%	36.76%	18.79%	30.50%
Free Cash Flow	51,983	44,313	48,122	30,887	15,603	10,183
Free Cash Flow Per Share	23.82	20.32	22.05	14.15	7.15	4.67
Dividend Per Share	3.636	3.636	2.853	1.023	0.572	1.175
Dividend Growth	27.45%	27.45%	178.99%	78.89%	-51.36%	218.61%
Gross Margin	26.51%	24.70%	21.12%	12.95%	29.80%	30.13%
Operating Margin	21.99%	20.72%	21.09%	3.67%	21.02%	21.35%
Profit Margin	13.35%	14.11%	11.72%	7.36%	14.01%	14.56%
Free Cash Flow Margin	30.21%	26.59%	31.12%	33.04%	43.44%	34.99%
EBITDA	56,829	60,826	56,434	23,238	11,205	9,328
EBITDA Margin	33.03%	36.49%	36.49%	24.86%	31.20%	32.05%
D&A For EBITDA	18,984	26,288	23,822	19,804	3,657	3,114
EBIT	37,844	34,538	32,613	3,434	7,549	6,214
EBIT Margin	21.99%	20.72%	21.09%	3.67%	21.02%	21.35%
Effective Tax Rate	36.56%	30.50%	-	-	-	8.37%
Revenue as Reported	172,067	166,671	154,653	93,487	35,921	29,104

Source: S&P Global Market Intelligence. Standard template. Financial Sources.